Quoin Pharma Q2 net loss $3.7M; QRX003 advances with FDA/EMA designations

Quoin Pharmaceuticals, Ltd.

Net loss Q2 2025 $3.7M vs $2.0M YoY; cash $7.8M supports operations into Q1 2026.
Positive 6-month pediatric Netherton data: skin improvement, reduced itch, no adverse events.
FDA cleared second pivotal study (CL-QRX003-002); NDA filing targeted later 2026.
EMA granted Orphan Drug Designation; FDA granted Rare Pediatric Disease Designation for QRX003.
Positive 12-week Peeling Skin Syndrome data: improved disease severity and quality of life.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.